Skip to main content

PRV-PD101 Prevail Therapeutics, Inc. A Phase 1/2a Open-Label, Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients with Parkinson’s Disease with at Least One GBA1 Mutation

NCT04127578

Prevail Therapeutics, Inc. A Phase 1/2a Open-Label, Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients with Parkinson’s Disease with at Least One GBA1 Mutation

Associated Conditions

Parkinsons

Principal Investigator

Bruce Hoffen

Sponsor

Prevail Therapeutics

You are being asked to consider whether you would like to participate in a clinical research study (also known as a clinical trial) of a study drug called PR001A because you have Parkinson’s disease. PR001A is being developed for the possible treatment of Parkinson’s disease in patients with the presence of a specific gene mutation called GBA1. This study is being done by a company that conducts drug research studies (called a 'Sponsor'). The Sponsor for this study is a company called Prevail Therapeutics, Inc. If you have any questions about being a subject in this study, you should ask the study doctor. If you do not understand something in this form, you should ask the study doctor. You should talk about participating in the study with anyone you choose before you decide.

This study is currently enrolling.